Prospects for the future in antiviral chemotherapy

  • P. Wildy

Abstract

I have been asked to sum up the session on antiviral drugs and to speculate on the future prospects in antiviral chemotherapy. We have already entered the era of antiviral chemotherapy even though as yet we can trust only a small proportion of virus infections. No longer has one to be an optimist to declare that the proportion of treatable infections will increase as knowledge accumulates. Indeed, we are now in the same kind of position with the viruses that we were with the bacteria some fifty years ago. Thus if we wish to peer into the future it may be well to look back to see the way forward. There are many obvious differences between antibacterial and antiviral chemotherapy. However numerous common problems are likely to arise.

Keywords

Tuberculosis Interferon Pyrimidine Thymidine Purine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. ABRAHAM, E.P. (1958). The mode of action of antibacterial substances in vitro. In General Pathology. Florey, H.W. (ed.) pp. 896–918, London: Lloyd-Luke.Google Scholar
  2. APOSHIAN, H.V. & KORNBERG, A. (1962). Enzymatic synthesis of deoxyribonucleic acid. IX The polymerase formed after T2 bacteriophage infection of E. coli; a new enzyme. J. biol. Chem., 337, 519–525.Google Scholar
  3. APPLEYARD, G. & WAY, H. (1966). Thiosemicarbazone resistant rabbit pox virus. Br. J. exp. Path., 7, 144–151.Google Scholar
  4. ASHTON, W.T., KARKAS, J.D., FIELD, A.K. & TOLMAN, R.L. (1982). Activation by thymidine kinase and potent antiherpetic activity of 2-nov2′deoxyguanosine (2 NDG) Biochem. biophys. Res. Commun., 108, 1718–1721.Google Scholar
  5. COEN, D.H. & SCHAFFER, P.A. (1980). Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc. natn. Acad. Sci. U.S.A., 77, 2265–2269.Google Scholar
  6. DARNELL, J.E. (1965). Biochemistry of animal virus reproduction. In Viral and rickettsial infections of man 4th edn. Horsfall, F.L. & Tamm, I. (eds) pp. 233–266, Philadephia: Lippencott.Google Scholar
  7. De CLERCQ, E. (1982a). Specific targes for antiviral drugs. Biochem. J., 205, 1–13.PubMedPubMedCentralCrossRefGoogle Scholar
  8. De CLERCQ, E. (1982b). Selective antiherpes agents. Trends in Pharmac. Sci., 3, 492–495.CrossRefGoogle Scholar
  9. De CLERCQ, E. (1983). Pyrimidine nucleoside analogues as antiviral agents. In Targets for the design of antiviral agents. De Clercq, E & Walker, J. (eds) pp. 203–230, Nato.Google Scholar
  10. DERSE, D., BASTOW, K.F. & CHENG, Y-C. (1982). Characterization of the DNA-polymerase induced by a group of herpes simplex virus type 1 variants selected for growth in the presence of phosphonoformic acid. J. biol. Chem., 257, 10251–10261.Google Scholar
  11. DOUGLAS, J.M., CRICHLOW, C., BENEDETTI, J., MERTZ, G.J., CONNOR, J.D., HINTZ, M.A., FAHNLANDER, A., REMINGTON, M., WINTER, C. & COREY, L. (1984). A double blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. New. Engl. J. Med., 310, 1551–1556.Google Scholar
  12. DRACH, J.C. (1983). Purine nucleoside analogs as antiviral agents. In Targets for the design of antiviral agents. De Clercq, E. & Walker, J. (eds) pp. 231–257.Google Scholar
  13. FIDDIAN, A.P., BRIDGEN, D., YEO, J.M. & HICKMOTT, E.A. (1984). Acyclovir; an update of the clinical applications of this antiherpes agent. Antiviral Res., 4, 99–117.Google Scholar
  14. FIELD, H.J. (1982). Development of clinical resistance to acyclovir in herpes virus-infected mice receiving oral therapy. Antimicrob. Ag. Chemother., 21, 744–752.CrossRefGoogle Scholar
  15. FIELD, H.J., ANDERSON, J.R. & EFSTATHIOU, S. (1984). A quantitative study of the effects of several nucleoside analogues on established herpes encephalitis in mice. J. gen. Virol., 65, 707–719.Google Scholar
  16. FIELD, H.J. & DARBY, G. (1980). Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob. Ag. Chemother., 17, 209–216.Google Scholar
  17. FIELD, H.J., DARBY, G. & WILDY, P. (1980). Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus. J. gen. Virol., 49, 115–124.Google Scholar
  18. HELD, H.J. & LAY, E. (1984). The characterization of latent infections in mice after inoculation with herpes simplex virus which is clinically resistant to acyclovir. Antiviral Res., 4, 43–52.Google Scholar
  19. FIELD, H.J. & WILDY, P. (1978). The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J. Hyg. Camb., 81, 267–277.Google Scholar
  20. HALL, M.J. (1984). Opportunities for the development and use of anti-herpes virus drug combinations. J. Antimic. Chemother. 13, 529–534.CrossRefGoogle Scholar
  21. HONESS, R.W. & WATSON, D.H. (1974). Absence of a requirement for host polypeptides in the herpes virus thymidine kinase. J. gen. Virol., 24, 215–220.Google Scholar
  22. ISAACS, A. & LINDENMANN, I. (1957). Virus interference. I. The interferon. Proc. R. Soc. Lond., 147, Series B 258–267.Google Scholar
  23. JAMIESON, A.T. & SUBAK-SHARPE, J.H. (1974). Biochemical studies on the herpes simplex virus-specified deoxypyridine kinase activity. J. gen. Virol., 24, 481–492.Google Scholar
  24. JAMIESON, A.T., GENTRY, G.A. & SUBAK-SHARPE, J.H. (1974). Induction of both thymidine and deoxycytidine kinase activity by herpes virus. J. gen. Virol., 24, 465–480.Google Scholar
  25. KEIR, H.M. & GOLD, E. (1963). DNA nucleotidyltransferase and deoxyribonuclease from cultured cells infected with herpes simplex virus. Biochim. biophys. Acta., 72, 263–276.Google Scholar
  26. KEIR, H.M., SUBAK-SHARPE, J.H., SHEDDEN, W.I.H., WATSON, D.H. & WILDY, P. (1966). Immunological evidence for a specific DNA polymerase produced after infection by herpes simplex virus. Virology, 30, 154–157.Google Scholar
  27. KIT, S. & DUBBS, D.R. (1963). Acquisition of thymidine kinase activity by herpes simplex infected mouse fibroblast cells. Biochem. biophys. Res. Commun., 11, 55–59.Google Scholar
  28. KLEMPERER, H.G., HAYNES, G.R., SHEDDEN, W.I.H. & WATSON, D.H. (1967). A virus specific thymidine kinase in BHK21 cells infected with herpes simplex virus. Virology, 31, 120–128.Google Scholar
  29. LARDER, B.A., CHENG, Y-C & DARBY, G. (1983). Characterization of abnormal thymidine kinase induced by drug-resistant strains of herpes simplex virus type 1. J. gen. Virol., 64, 523–532.Google Scholar
  30. MELNICK, J.L., CROWTHER, D. & BARRERA-ORO, J. (1961). Rapid development of drug-resistant mutants of poliovirus. Science, 134, 551.Google Scholar
  31. SCHNIPPER, L.E. & CRUMPACKER, C.S. (1980). Resistance of herpes simplex virus to acycloguanosine: Role of viral thymidine kinase and DNA polymerase loci. Proc. natn. Acad. Sci. U.S.A., 77, 2270–2273.Google Scholar
  32. SIM, I.S. & RAPER, R.H. (1984). 5-substituted deoxyuridines-structural requirements for antiviral activity against herpes simplex virus type 1 and 2 and possible biochemical basis for relative potency. Antiviral Res., 4, 159–168.Google Scholar
  33. STRAUS, S.I., TAKIFF, H.E., SEIDLIN, M., BACHRACH, S., LININGER, L., DiGIOVANNA, J.J. & 5 OTHERS. (1984). Suppression of frequently recurring genital herpes. A placebo-controlled double blind trial of oral acyclovir. N. Engl. J. Med., 310, 1545–1550.Google Scholar
  34. TAMM, I. & EGGERS, H.J. (1965). Selective inhibition of viral reproduction. In Viral and rickettsial infections of man 4th edn. Horsfall, F.L. & Tamm, I. (eds) pp. 305–338, Philadelphia: Lippencott.Google Scholar
  35. TENSER, R.B., MILLER, R.L. & RAPP, F. (1979). Trigeminal ganglia infected by thymidine kinase-negative mutants of herpes simplex virus. Science, 205, 915–917.Google Scholar

Copyright information

© Macmillan Publishers Limited 1984

Authors and Affiliations

  • P. Wildy
    • 1
  1. 1.Department of PathologyCambridgeUK

Personalised recommendations